NICE grants Celgene long-awaited thumbs-up for Revlimid in untreated myeloma
admin 17th May 2019 Uncategorised 0The old adage “better late than never” may be overused, but for Celgene, it certainly applies to England’s cost watchdogs and their stance toward the company’s multiple myeloma flagship drug Revlimid.
More: NICE grants Celgene long-awaited thumbs-up for Revlimid in untreated myeloma
Source: fierce